Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ladarixin - Dompe Farmaceutici

Next Previous
Drug Profile

Ladarixin - Dompe Farmaceutici

Alternative Names: DF-2156A; DF-2156Y; LDX - Dompe Farmaceutici; Meraxin

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dompe Farmaceutici
  • Class Anti-inflammatories; Antihyperglycaemics; Eye disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ocular inflammation
  • Discontinued Bullous pemphigoid; Insulin resistance; Malignant melanoma; Spinal cord injuries; Type 1 diabetes mellitus

Most Recent Events

  • 09 Apr 2026 Dompe Farmaceutici withdrew phase II trial prior to enrolment in Type I diabetes mellitus (In adolescents, In adults, Newly diagnosed) in Italy (PO) (CTIS2025-524298-18-00)
  • 25 Feb 2026 Phase-I clinical trials in Ocular inflammation (In volunteers) in Netherlands (Ophthalmic) (CTIS2025-524527-46-00)
  • 30 Jan 2026 Discontinued - Phase-I for Type 1 diabetes mellitus (In volunteers) in Switzerland (PO) (Dompe Farmaceutici pipeline, January 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top